Regulatory Approval FDA Approval Oncology Eli Lilly Market Competition Phase 3 Trials Phase II Trials FDA Regulations Patient Outcomes Obesity Treatments Preclinical Research Cancer Therapies Investigational Drugs Orforglipron Late-Stage Testing Market Risks Targeted Therapies Cancer Drugs GLP-1 Drugs RNA Therapeutics Prescription Medications Efficacy and Safety Metabolic Diseases Efruxifermin Influenza Treatment Efficacy Studies Food Allergy Treatments Pipeline Management Diagnostics Semaglutide Cancer Treatments Efficacy Phase I/II Trials Drug Pipeline FDA Approval Process AGAMREE Market Analysis Pediatric Programs Lung Cancer Treatment Psychedelic Research Phase 1/2 Trials Obesity Treatment Phase 3 Studies Injectable Drugs Patient Safety Pharmacokinetics Market Expectations Investigational New Drugs Phase 1 Trials Treatment Options
The agreement hands later-stage development and commercialization to Lilly while expanding its genetic-medicine pipeline and funding Ascidian’s early research efforts.
